TME Pharma gets FDA Fast Track for Glioblastoma
TME Pharma N.V. with research sites in France and Germany (listed at Euronext Growth Paris: ALTME) is developing novel therapies for treatment of...
2:1 for new genomic techniques
At the end of December, genetic engineering sceptics celebrated that the Council of Agriculture Ministers narrowly failed to reach a qualified...
Solar Foods starts Factory01
Following market authorisation in Singapore two years ago, the Finnish company Solar Foods Oy and the Japanese food giant Ajinomoto Group want to...
Innate immunity merger raises €75m
Dutch Oxitope and Norwegian Arxx announced their merger to form Calluna Pharma Inc with the goal to develop therapies for inflammatory and fibrotic...
£26m for Cystic Fibrosis Drug Trial
With funding led by Panakes Partners and involvement from current investors, Enterprise Therapeutics Ltd. has received £26m (~€30.5m) for the Phase...
Swiss vaccine developer Limma Tech get CARB-X grant
LimmaTech said, it will use the grant to advance preclinical development of its hexavalent vaccine candidate targeting Neisseria gonorrheae. Using...
Lonza and Oxford Nanopore collaborate to advance mRNA Therapeutics
The significance of mRNA technology has been highlighted in recent years, particularly with its role in rapidly developing and bringing COVID-19...